{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:59:17Z","timestamp":1758776357830,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ygyno.2021.09.024","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T08:22:31Z","timestamp":1635150151000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)"],"prefix":"10.1016","volume":"164","author":[{"given":"Olivier","family":"Tr\u00e9dan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Provansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Abdeddaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Lardy-Cleaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Hardy-Bessard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Venat-Bouvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Pop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Largillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Zannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Anota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Treilleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pissaloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Houlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude-Marie","family":"Savoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-Briac","family":"Levach\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.09.024_bb0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2001.1787","article-title":"Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy","volume":"84","author":"Tuxen","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0025","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2021.09.024_bb0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/ijgc-00009577-200602001-00029","article-title":"Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up","volume":"16","author":"Rudlowski","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0040","article-title":"Incorporation of Bevacizumab in the primary treatment of ovarian Cancer","volume":"11","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0045","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 investigators, a phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0050","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0055","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0065","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose\u2013escalation study of Regorafenib (BAY 73\u20134506), an inhibitor of oncogenic, Angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin. Cancer Res."},{"year":"2010","series-title":"Tamoxifen for Relapse of Ovarian cancer, Cochrane Database of Systematic Reviews","author":"Williams","key":"10.1016\/j.ygyno.2021.09.024_bb0070"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0075","first-page":"3183","article-title":"Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor","volume":"60","author":"Hyder","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14737140.2017.1272414","article-title":"Endocrine therapy in epithelial ovarian cancer","volume":"17","author":"Langdon","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2010.08.002","volume":"119","author":"Hurteau","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0100","doi-asserted-by":"crossref","first-page":"26388","DOI":"10.18632\/oncotarget.4557","article-title":"The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: characterization, validation, and prognostic value","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0105","doi-asserted-by":"crossref","first-page":"x89","DOI":"10.1093\/annonc\/mdx663.013","article-title":"Interim analysis of a single-arm phase 2 clinical trial of Regorafenib in patients with epithelial ovarian Cancer","volume":"28","author":"Tan","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/cbt.26708","article-title":"Multi-kinase inhibition in ovarian cancer","volume":"15","author":"Dent","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2021.09.024_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2020.08.021","article-title":"Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy","volume":"139","author":"Tjokrowidjaja","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.024_bb0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.09.024_bb0125","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821014025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821014025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:46Z","timestamp":1758772726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821014025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0090825821014025"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}